国际肿瘤学杂志

国际肿瘤学杂志››2015,Vol. 42››Issue (8): 631-634.doi:10.3760/cma.j.issn.1673422X.2015.08.019

• 综述 •上一篇下一篇

程序性死亡配体1及其抑制剂在非小细胞肺癌中的研究进展

耿睿,潘莉,宋霞

  1. 030013太原，山西医科大学附属肿瘤医院呼吸二病区
  • 出版日期:2015-08-08发布日期:2015-06-29
  • 通讯作者:宋霞，Email:songxia76@hotmail.com E-mail:songxia76@hotmail.com

Advances of programmed death ligand 1 and its inhibitor in nonsmall cell lung cancer

GENG Rui, PAN Li, SONG Xia

  1. Second Ward of Department of Respiratory, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China
  • Online:2015-08-08Published:2015-06-29
  • Contact:Song Xia E-mail:songxia76@hotmail.com

PDF

1574

摘要：程序性死亡配体1（PDL1）以细胞膜型PDL1和可溶性PDL1两种形式在NSCLC中高表达，通过与其受体结合参与肿瘤免疫逃逸。目前PDL1抑制剂已进入NSCLC的Ⅰ期临床试验并反应良好，其治疗敏感性与肿瘤组织PDL1的表达状态显著相关，因而PDL1有望成为预测其药物疗效的生物学标志物。

关键词:癌,非小细胞肺,免疫抑制剂,程序性死亡配体1

Abstract:Programmed deathligand 1 (PDL1), which is highly expressed in NSCLC, can be divided into two categories: membrane PDL1 and soluble PDL1. PDL1 participates in tumor immune escape through combining with its receptor. PDL1 immune checkpoint inhibitors have entered the phase Ⅰ studies and showed a good application prospect. It is also found that the sensitivity of PDL1 immune checkpoint inhibitors is strongly associated with the expression of PDL1 in tumor. Therefore, PDL1 can be used as a biomarker to predict its curative effect.

Key words:Carcinoma, nonsmall cell lung,Immunosuppressive agents,Programmed death ligand 1